Everything you need to know about Palantir, the secretive company coming for all your data
By Sara Morrison,
Vox
| 07. 16. 2020
In the earlier days of the Covid-19 pandemic, many of the country’s public health departments, still reliant on fax machines, were woefully unprepared for the massive amounts of data they needed to process. Looking for a tidy private sector solution to a messy government problem, the Department of Health and Human Services (HHS) paid a shadowy Silicon Valley company with ties to the Trump administration to build something new. That company is called Palantir Technologies, and if you don’t know much about it, that’s by design.
Palantir specializes in data-gathering and analysis, most of which it does for government agencies. It has about $1.5 billion in federal government contracts alone, including, recently, with the Space Force and the Navy. Now, as new Covid-19 case numbers break records daily, Palantir is trying to help organize the information with a new platform called HHS Protect, which will be run by another private company called TeleTracking. This partnership has effectively replaced the Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network, per the Trump administration’s orders to hospitals...
Related Articles
By Kiana Jackson and Shannon Stubblefield, New Disabled South | 02.09.2026
"MC0_8230" via Wikimedia Commons licensed under CC by 2.0
This report documents a deliberate assault on disabled people in the United States. Not an accident. Not a series of bureaucratic missteps. An assault that has been coordinated across agencies...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...